Cargando…

HER2 mutations in Chinese patients with non-small cell lung cancer

BACKGROUND: ERBB2 (HER2) is a driver gene identified in non-small cell lung cancer (NSCLC). The prevalence, clinicopathology, genetic variability and treatment of HER2-positive NSCLC in Chinese population are unclear. PATIENTS AND METHODS: Eight hundred and fifty-nine patients with pathologically co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zhengbo, Yu, Xinmin, Shi, Zhiyong, Zhao, Jun, Zhang, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363651/ https://www.ncbi.nlm.nih.gov/pubmed/27825109 http://dx.doi.org/10.18632/oncotarget.11313

Ejemplares similares

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
por: Song, Zhengbo, et al.
Publicado: (2016)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2016)

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
por: Zhang, Shirong, et al.
Publicado: (2022)

Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy
por: Song, Zhengbo, et al.
Publicado: (2016)

Chemotherapy and prognosis in advanced thymic carcinoma patients
por: Song, Zhengbo, et al.
Publicado: (2015)

PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2020)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis
por: Wang, Wenxian, et al.
Publicado: (2018)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
por: Jin, Ying, et al.
Publicado: (2016)

Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study
por: Gu, Xiaodong, et al.
Publicado: (2022)

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
por: Song, Zhengbo, et al.
Publicado: (2021)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
por: Song, Zhengbo, et al.
Publicado: (2016)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Treatment and Prognosis of Solid and Cystic Brain Metastases in Patients with Non-Small-Cell Lung Cancer
por: Xu, Yi-Bing, et al.
Publicado: (2021)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

Rare frequency of gene variation and survival analysis in thymic epithelial tumors
por: Song, Zhengbo, et al.
Publicado: (2016)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer
por: Li, Jianqiang, et al.
Publicado: (2020)

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
por: Cappuzzo, F, et al.
Publicado: (2005)

Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non–Small Cell Lung Cancer
por: Lin, Chen, et al.
Publicado: (2020)

Tislelizumab plus chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy
por: Zhong, Hua, et al.
Publicado: (2023)

Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer
por: Pécuchet, Nicolas, et al.
Publicado: (2015)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

Efficacy and Safety of High-Dose Controlled-Release Oxycodone in the Treatment of Moderate to Severe Pain in Patients with Advanced Cancer: A Retrospective Study
por: Wang, Wenxian, et al.
Publicado: (2018)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
por: Wang, Rui, et al.
Publicado: (2015)

Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
por: Hao, Yue, et al.
Publicado: (2023)

Consensus for HER2 alterations testing in non-small-cell lung cancer
por: Ren, S., et al.
Publicado: (2022)

The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
por: Cai, Dongjing, et al.
Publicado: (2019)

Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study
por: Wang, Wenxian, et al.
Publicado: (2022)

Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non‐small cell lung cancer: A real‐world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial
por: Ai, Xinghao, et al.
Publicado: (2021)

The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
por: Yu, Xiaoqing, et al.
Publicado: (2022)

Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non–small-cell lung carcinoma
por: Luo, Ruihan, et al.
Publicado: (2020)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer
por: Yin, Zi-Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_79cr18hk7skap8qqmvt0s95gnk